Combined treatment of TKIs with Cilengitide overcomes afatinib-resistance in EGFR-mutated NSCLC cells.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Combined treatment of TKIs with Cilengitide overcomes afatinib-resistance in EGFR-mutated NSCLC cells.
- Published In:
- Molecular biology reports, 53(1), 233 (2025)
- Authors:
- Kang, Hye Eun, Seo, Yujin, Kim, Yeonsoo, Kim, Jiyeon
- Database ID:
- RPEP-11706
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11706APA
Kang, Hye Eun; Seo, Yujin; Kim, Yeonsoo; Kim, Jiyeon. (2025). Combined treatment of TKIs with Cilengitide overcomes afatinib-resistance in EGFR-mutated NSCLC cells.. Molecular biology reports, 53(1), 233. https://doi.org/10.1007/s11033-025-11405-2
MLA
Kang, Hye Eun, et al. "Combined treatment of TKIs with Cilengitide overcomes afatinib-resistance in EGFR-mutated NSCLC cells.." Molecular biology reports, 2025. https://doi.org/10.1007/s11033-025-11405-2
RethinkPeptides
RethinkPeptides Research Database. "Combined treatment of TKIs with Cilengitide overcomes afatin..." RPEP-11706. Retrieved from https://rethinkpeptides.com/research/kang-2025-combined-treatment-of-tkis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.